Streetbeat News

Products Services

NVCR

NovoCure shares rise following FDA approval of Optune Lua for metastatic non-small cell lung cancer treatment. HC Wainwright & Co. upgrades the stock to Buy and raises the price target from $24 to $30.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:39 am

IREN

IREN's AI Cloud Services Division is projected to generate around $32 million in annualized hardware profit by the end of December 2024, contributing approximately 10% to the company's overall earnings.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:35 am

CYTK

Cytokinetics is set to provide updates on its cardiac myosin modulation programs and the global commercial launch readiness for Aficamten during its Investor and Analyst Day.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:33 am

ALZN

Alzamend Neuro (NASDAQ:ALZN) has released the full data set from its Phase 2A trial for AL001, a treatment for dementia related to Alzheimer's. The study found the treatment to be safe and well-tolerated, paving the way for further clinical trials. Alzamend plans to conduct five additional trials to compare lithium levels in the brain with those from a marketed lithium salt.

Portfolio Pulse from Vandana Singh

October 16, 2024 | 11:30 am

ALZN

Alzamend Neuro announced that the identified dose for their treatment is unlikely to require lithium therapeutic drug monitoring, which could simplify the treatment process and potentially enhance patient compliance.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:30 am

ALZN

Alzamend Neuro has confirmed positive topline results from June 2023, identifying a maximum tolerated dose as assessed by an independent safety review committee.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:30 am

ALZN

Alzamend Neuro has announced the full data set for its Phase IIA clinical trial of AL001, a treatment for dementia related to Alzheimer's. This development is a significant step in the company's research efforts.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:30 am

INTC

JBHT

NVCR

QQQ

SPY

US stock futures indicate a mixed opening after a tech sell-off led by ASML's weak forecast. SPDR S&P 500 ETF Trust (SPY) and Invesco QQQ ETF (QQQ) show slight premarket gains. J.B. Hunt Transport Services (JBHT) and NovoCure (NVCR) see significant premarket rises due to positive earnings and FDA approval, respectively. Intel (INTC) declines on Qualcomm's investment delay. Oil prices continue to pressure energy stocks.

Portfolio Pulse from Shanthi Rexaline

October 16, 2024 | 11:29 am

NVCR

The FDA has approved NovoCure's Optune Lua, a portable device that uses tumor-treating electric fields, for use with certain inhibitors or docetaxel in treating metastatic non-small cell lung cancer. The approval follows positive results from the Phase 3 LUNAR study, showing significant improvements in overall survival rates. NovoCure's stock (NVCR) rose by 26.20% following the news.

Portfolio Pulse from Vandana Singh

October 16, 2024 | 11:28 am

GM

TSLA

Tesla dominated the US EV market in Q3 2024, with the Model Y, Model 3, and Cybertruck being the top three best-selling models. Tesla's overall sales increased by 6.6% compared to the previous year. General Motors was the second best-selling EV maker, with a significant increase in GMC's Hummer EV sales.

Portfolio Pulse from Anan Ashraf

October 16, 2024 | 11:21 am